- The FDA with support from National Medicine Regulatory Agency (NMRA) has given approval to KNUST researchers to try out a herbal mixture as a treatment for COVID-19
- This approval was given directly to the School of Public Health at the university
- The herb in question is Cryptolepis sanguinolenta, known locally as Nibima, Kadze and Gangamau
Trending topics on the go: How we write news at YEN.com.gh
The Food and Drugs Authority (FDA) has given approval to some researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology to try out a COVID-19 treatment.
In a letter dated February 1, 2021, the FDA indicated that the researchers can commence clinical trials of the potential treatment which is a herbal mixture used in the past to combat malaria.
With support from the National Medicine Regulatory Agency (NMRA), Cryptolepis sanguinolenta, known locally as Nibima, Kadze and Gangamau will be investigated as an efficient remedy from the global pandemic.
This development seems to be timely as Ghana's daily increase in the COVID-19 infections has jumped from 200 to about 700 in recent days.
According to the Disease Surveillance Department of the Ghana Health Service, the number of active cases currently is 5,378 with 794 cases freshly confirmed within 24 hours.
So far, Ghana has lost 416 citizens to the coronavirus and this number sadly keeps increasing as well.
As it was earlier reported, 37-year-old Ghanaian CEO called Samuel Mensah who was based in the United Kingdom has died of the novel coronavirus after a scheduled interview on the virus.
According to Good Evening Ghana's verified Facebook handle who confirmed the news of Samuel's passing, the deceased was billed to be interviewed on Metro TV’s on Thursday, January 28, 2021, at 9 pm.
Sadly, Paul Adom-Otchere later announced that Sam himself has passed on as a result of the coronavirus which he contracted earlier.
Enjoy reading our stories? Join YEN.com.gh's Telegram channel!